Financial Performance - The Group's revenue for 2022 was RMB 841,586,000, representing a 19.3% increase from RMB 705,456,000 in 2021[27]. - Sales of Chinese medicines and pharmaceutical products increased to RMB 841,586,000 in 2022, up from RMB 705,456,000 in 2021, representing a growth of approximately 19.3%[43]. - The profit attributable to owners of the Company for the year ended December 31, 2022, was RMB 193,565,000, up from RMB 143,283,000 in 2021, reflecting a growth of approximately 35.2%[52]. - Other income and gains for the year were approximately RMB 59,737,000, compared to RMB 51,616,000 in 2021[142]. - The gross profit margin for the year ended December 31, 2022, was approximately 77%, a decrease of 5.2% from 82.2% in 2021[142]. - Basic earnings per share rose to RMB 34.55 cents from RMB 25.57 cents, marking an increase of 35.2%[162]. Assets and Liabilities - Total assets increased to RMB 2,372,841,000 in 2022 from RMB 2,072,313,000 in 2021[142]. - The Group's total liabilities and equity as of 31 December 2022 were not disclosed in the provided documents, but the increase in assets suggests potential growth in equity[75]. - The Group's total liabilities to total assets ratio was 32% (2021: 30%) calculated from total liabilities of RMB 760,543,000 (2021: RMB 618,564,000) and total equity and liabilities of RMB 2,372,841,000 (2021: RMB 2,072,313,000)[144]. - The Group's gearing ratio, derived from total borrowings to total net assets, was 0.02% (2021: 0.03%) as of December 31, 2022[144]. Investments - As of December 31, 2022, the company held Wealth Management Products totaling approximately RMB263,074,000, with unrealized gains from fair value changes amounting to approximately RMB3,074,000[5]. - The Group's investment in time deposits as of December 31, 2022, was approximately RMB866,856,000, up from RMB806,918,000 in 2021[95]. - The Group's total initial investment cost in wealth management products was RMB 260,000,000[164]. - The fair value of unlisted financial assets increased to RMB 263,074,000 in 2022 from RMB 176,533,000 in 2021[171]. Research and Development - The Group invested approximately RMB40,440,133 in research and development projects during the year[97]. - The R&D department successfully developed the Compound Huonaoshu capsule, which significantly contributed to the Group's revenue and led to its listing in Hong Kong[97]. - The Company has enhanced its R&D capabilities by building a new R&D inspection center with advanced equipment for new product trials[142]. - The company has been actively involved in the research and development of new medicines, including three new products: Infantile spleen-strengthening oral solution, Colon Recovery Capsule, and Ginseng Glycopeptide Injection[124]. Employee and Management - The Group's contribution to retirement benefits schemes for the year ended 31 December 2022 amounted to RMB2,720,000, a significant increase from RMB597,000 in 2021, representing a growth of approximately 354%[67]. - Salaries, allowances, and other benefits increased to RMB4,479,000 in 2022 from RMB2,832,000 in 2021, reflecting a growth of about 58%[65]. - The Company has a total of 823 employees, with remuneration based on market conditions and individual performance, including discretionary bonuses and other benefits[144]. - The executive general manager, Zhang Yi, has been with the company since 2015, contributing to its strategic direction and management[122]. Inventory and Assets Management - Total inventories increased to RMB 138,880,000 in 2022 from RMB 87,168,000 in 2021, with a provision for obsolete and slow-moving inventories of RMB 5,893,000[115]. - The carrying amount of goodwill as of December 31, 2022, remained unchanged at RMB 6,254,000, with no impairment loss recognized[136]. - The carrying amount of bearer biological assets, specifically ginseng, remained stable at RMB15,080,000 for both 2022 and 2021[71]. - The company recognized a provision for obsolete and slow-moving inventories amounting to approximately RMB 5,038,000, compared to RMB 735,000 in 2021[138]. Taxation - The PRC corporate income tax for the current year was RMB 20,957,000, with a deferred taxation of RMB 26,727,000, compared to RMB 30,520,000 in 2021[34]. - Deferred income tax assets are recognized only if it is probable that future taxable profit will be available[19]. - The net deferred tax assets/(liabilities) stood at RMB 23,289,000 in 2022, compared to a net liability of RMB 2,353,000 in 2021[199]. Corporate Governance and Compliance - The Group is committed to maintaining high environmental and social standards, complying with all relevant laws and regulations related to health, safety, and the environment[144]. - The Group encourages participation in environmental and social activities that benefit the community as a whole[144]. - The Group has established a Risk Management Committee to enhance the assessment and management of investments in Wealth Management Products and time deposits[95].
吉林长龙药业(08049) - 2022 - 年度财报